newsfilter
← Latest News
Business Wire·

Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights

- Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study - Initiated GLP toxicity studies and GMP manufacturing of SAT-3247 - Continues to be on track to initiate first-in-human clinical trials mid-2024 -